Fordham Law School

FLASH: The Fordham Law Archive of Scholarship and History
Faculty Scholarship
2019

Science Fiction: Fictitious Experiments in Patents
Janet Freilich
Lisa L. Ouellette

Follow this and additional works at: https://ir.lawnet.fordham.edu/faculty_scholarship
Part of the Law Commons

INSIGHTS

P OLICY FORUM
INTELLECTUAL PROPERTY

Science fiction: Fictitious
experiments in patents
Prophetic examples may unnecessarily distort understanding
By Janet Freilich1 and
Lisa Larrimore Ouellette2

1

Fordham University School of Law, New York, NY, USA.
Stanford Law School, Stanford University, Stanford, CA, USA.
Email: jfreilich1@fordham.edu; ouellette@law.stanford.edu
2

1036

PROPHETIC EXAMPLES MAY BE CONFUSING
Contrary to the assertions of some patent
scholars that scientists never read patents, survey evidence shows that many researchers do look to the patent literature
for general research, to browse information about cutting-edge technologies, and
to learn how other researchers solved particular problems (12). Training on how to
search patents is even provided in some
undergraduate science classes (12). But the
usefulness of patents as a source of technical information is diminished if scientific
readers are unable to distinguish actual
data from predicted results.
Although scientists read patents—and
therefore also read prophetic examples—
the verb tense rule that distinguishes these
predicted results from actual data is unlikely to be familiar to the average scientist. Most patent drafters do not seek to
intentionally mislead readers, but they are
writing for a legal audience and using conventions that may be unclear to nonlegal
readers. Prophetic examples are confusing
because they mimic real experiments, particularly by including excessive detail—for
example, age of the hypothetical patient (“a
46-year-old woman…”)—and specific, nu-

WHY USE PROPHETIC EXPERIMENTS?
To explore whether benefits for patentees
from prophetic examples can be obtained
through less confusing patent-drafting
methods, we interviewed professional patent prosecutors who write U.S. patents. As
described in the supplementary materials,
we identified prophetic examples as those
written in the present or future tense. We
then contacted a randomly selected sample
of patent prosecutors in the fields of chemistry and biology who, in patent applications filed between 2011 and 2013, either
never used prophetic examples or used
prophetic examples in more than half of
applications filed. We conducted 26 interviews, with a yield rate of 67%.
Prosecutors who use prophetic examples
consistently explained that such examples
make clear how an inventor expects an idea
to work in scenarios for which there is not
time or money to test before the desired
patent filing deadline. Because patents
can cover all variations of an invention
described in enough detail for others to
make and use without undue experimentation, prophetic examples with predicted
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lthough it may surprise scientists,
one can receive a patent in many
jurisdictions without implementing
an invention in practice and demonstrating that it works as expected.
Instead, inventors applying for patents are allowed to include predicted experimental methods and results, known as
prophetic examples, as long as the examples are not written in the past tense (1–3).
Allowing untested inventions to be patented may encourage earlier disclosures
about new ideas and provide earlier certainty regarding legal rights—which may
help small firms acquire financing to bring
their ideas to market. Yet granting patents
too early may also discourage researchers from doing the work to bring ideas to
fruition (4, 5). Even if allowing untested
inventions to be patented is desirable, we
think prophetic examples deserve closer
scrutiny, and clearer labeling, because of
the likelihood that they are unnecessarily
confusing—particularly to scientists, many
of whom read patents but are unlikely to
appreciate that not all the claims are based
on actual data.
The U.S. Patent and Trademark Office
(USPTO) formally recognized prophetic
examples in 1981, but the practice is considerably older. A patent application need
only contain sufficient information that a
skilled researcher in the field would recognize as credibly demonstrating how to
make and use the invention (6). Prophetic
examples are one way to help satisfy this
legal standard for inventions that have
not yet been demonstrated to work (2). Although prophetic examples that are close
variations on actual experiments are preferable, many prophetic examples appear
to be entirely hypothetical predictions.
Preliminary research suggests that these
examples are particularly prevalent in

chemistry and biology; an estimated 17%
of examples in U.S. patents in these fields
are prophetic, and almost one-quarter of
U.S. patents in these fields have at least
one prophetic example—making prophetic
examples a commonplace feature (for examples, see the box) (7).
Because of concerns about awarding
patents to unproven inventions, prophetic
examples are viewed with greater skepticism in Europe (8), Canada (9), Japan (10),
and China (11). However, because patents
with the same contents are often filed
in multiple regions, prophetic examples
originating in U.S. applications will often
be present in applications filed in other jurisdictions. Further, because patent offices
and examiners in those countries commonly read and cite patents from other
jurisdictions, countries skeptical of prophetic examples still feel their effects.

merical results (“blood pressure is reduced
within 3 hours…”). Some preliminary work
suggests that of 100 randomly selected patents with only prophetic examples—that is,
no actual data—that were cited in a scientific article or book for a specific proposition, 99 were not cited in a way that made
clear that the cited information was prophetic (7). To the contrary, these prophetic
patents were cited with phrases such as
“[d]ehydration reaction in gas phase has
been carried out over solid acid catalysts”
(7), suggesting that prophetic examples
mislead scientist readers.
Prophetic examples may also be confusing to other readers who are unfamiliar
with the tense rule, such as investors seeking to accurately evaluate complex technologies. Causing further misunderstanding,
the subtlety of prophetic examples may
literally be lost in translation for patent
applications that must be translated into
different languages because they are filed
in international jurisdictions. To be sure,
quantifying the cost of this confusion would
be challenging, especially because most
confused scientists, investors, and patent
examiners are likely unaware of the problem. But given the lack of a corresponding
benefit, there seems to be no reason to perpetuate the practice. Nothing in patent law
requires early-stage ideas to be described in
a way that might confuse these different audiences by mimicking factual experiments;
prophetic examples could be signaled more
clearly or avoided altogether.
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MORE CLARITY, LESS CONFUSION
The benefits flowing from prophetic examples exist because some patent systems
recognize and allow the use of hypothetical
experiments and data. Within these legal
systems, prosecutors, patent examiners,
and courts can already identify prophetic
examples through the tense rule, so requiring a more explicit distinction between
prophetic and nonprophetic examples
would have no legal impact; prophetic examples would continue to be recognized
and rewarded as such, just with lower risk
of confusion.

Patently Prophetic
The present tense used in patents
for a chemical synthesis, a medical
procedure, and a medical device suggests that the procedures likely had not
actually been conducted at the time of
filing a patent application.
U.S. Patent
No. 3,931,205
2.5 g of 2-(5H-[1]
benzopyrano[2,3-b]
pyridin-7-yl)acrylic acid
is dissolved in 20 ml of 0.5
N aqueous sodium hydroxide solution,
and 1 g of Raney nickel is added. The
solution is stirred in a hydrogen stream
at ordinary pressure and temperature
until absorption of 230 ml of hydrogen
is attained. The Raney nickel is removed
by filtration, and the filtrate is neutralized with hydrochloric acid. The resulting
crystalline precipitate is filtered off,
washed with water, and recrystallized
from aqueous dioxane to give 1.8 g of
2-(5H-[1]benzopyrano[2,3-b]pyridin-7-yl)
propionic acid melting at 183°–184°C.
U.S. Patent
No. 6,869,610
A 46-year-old woman
presents with pain
localized at the deltoid
region due to an arthritic condition. The muscle is not in spasm, nor
does it exhibit a hypertonic condition.
The patient is treated by a bolus injection of between about 50 units and 200
units of intramuscular botulinum toxin
type A. Within 1 to 7 days after neurotoxin administration the patient’s pain is
substantially alleviated. The duration of
significant pain alleviation is from about
2 to about 6 months.
U.S. Patent
No. 7,291,497
Each patch [for
drawing and sampling
0.1 ml of blood for
vancomycin] consists of two
parts. … Micro-needles automatically
draw small quantities of blood painlessly. A mechanical actuator inserts
and withdraws the needle … mak[ing]
several measurements after the patch
is applied. … Needles are produced
photolithographically in molds at [the
Stanford Nanofabrication Facility]. …
Blood flows through the micro-needles
into the blood reservoir. …

The impact of clarifying prophetic examples would also be felt outside the legal
systems that allow the practice. Scientists
previously unable to distinguish or unaware
of the distinction between prophetic and
real experiments would gain more information and clarity. Investors using patents as a
source of information about new technologies would find such information clearer
and more useful. And international patent
offices wrongly interpreting prophetic examples when tenses are lost in translation
would be able to avoid such errors.
What should be done? A simple and effective solution is to require that prophetic
examples in new patent applications be
clearly labeled, perhaps with a heading
such as “hypothetical experiment” or an
introductory phrase such as “it is expected
that these experiments would provide
these results.” In the United States, for example, this change could be implemented
by the USPTO along with its other rules for
patent formatting. The USPTO already requires that prophetic examples be labeled
(by avoiding the past tense), so our proposal does not add a labeling requirement;
it merely makes an existing requirement
more effective. Further, patent drafters
should be encouraged to be mindful of
clarity and avoid potentially confusing
phrases and details.
Just because some patents are not based
on actual results does not mean they need
to be confusing. Scientists regularly write
grant applications in a way that makes
clear what preliminary data they have already acquired and what the expected goal
of the proposed project is. Perhaps this is
an area in which the patent system could
learn from the scientific community. j
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results can extend the patent’s legal protection. For example, if an inventor has
made a particular protein in her laboratory but also believes that the protein will
work similarly if certain amino acids are
switched, a prosecutor can draft prophetic
examples with the alternate sequences
and a prediction of the expected outcome.
These examples help the inventor obtain
patent coverage beyond the specifics of
what has been done in the laboratory, including to block competitors from working
on similar technologies.
Interviewed prosecutors generally acknowledged the possibility that scientists
reading prophetic examples might be unable to correctly interpret the verb tense
rule, although they emphasized the legality
of the practice and their duty to obtain the
strongest possible patent for their clients.
They also agreed, however, that an equally
strong patent could be obtained with
prophetic examples that were explicitly
labeled as predictions that had not been
carried out. Interviewees who do not use
prophetic examples argued that there is no
legal reason to present these predictions
in the form of fictitious experiments with
specific results rather than in more general terms; to the contrary, prophetic examples carry some legal risk, such as if the
example turns out to be inoperative. Prosecutors were particularly wary of using
prophetic examples in patent applications
that would be filed internationally, given
the greater skepticism of these examples in
certain countries.
The only benefit to patentees that would
be reduced by requiring greater clarity
seems to be the benefit that comes from
confusion. For example, several prosecutors suggested that prophetic examples
could illustrate a technology’s promise to
potential investors, who might not be able
to distinguish between prophetic examples
and experiments actually conducted. This
potential confusion was considered a benefit to patentees, but this benefit does not
seem worth preserving.
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